When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 18 Mar 2025
Last updated: 04 Jun 2024

Summary

Definition

History and exam

Key diagnostic factors

  • infertility
  • failure to complete pubertal maturation
  • small testes
  • expressive speech delay in early childhood
  • micropenis
  • cryptorchidism

Other diagnostic factors

  • developmental delay
  • behavioural problems in childhood
  • tall stature
  • lack of facial and pubic hair
  • gynaecomastia
  • sexual dysfunction/reduced libido
  • high fat-to-muscle ratio/abdominal obesity
  • social/ psychological issues
  • fatigue

Risk factors

  • increased maternal age

Diagnostic investigations

1st investigations to order

  • chromosomal karyotype
  • serum total testosterone
  • serum LH/FSH

Treatment algorithm

Contributors

Authors

Alan D. Rogol, MD, PhD

Professor Emeritus

Departments of Pediatrics and Pharmacology

University of Virginia

Charlottesville

VA

Disclosures

ADR declares consultation for Antares Pharma (androgen therapy for adolescents), Ascendis Pharma (long-acting growth hormone therapy), BioMarin Pharmaceuticals (therapy for growth plate disorders), Pfizer Pharmaceuticals (long-acting growth hormone), Tolmar Pharmaceuticals (androgen therapy for adolescents), the US Anti-Doping Agency (testosterone and growth hormone in US elite athletes), and the World Anti-doping Agency (testosterone and growth hormone in International elite athletes); he is the Chair DSMB for oral growth hormone secretagogue for Lumos Pharma.

Gary E. Butler, MD, FRCPCH

Consultant in Paediatric and Adolescent Endocrinology

University College London Hospital

Clinical Professor of Child and Adolescent Health

UCL Great Ormond Street Institute of Child Health

London

UK

Disclosures

GEB declares that he has no competing interests.

Claus Højbjerg Gravholt​, MD, PhD

Professor and Consultant

Department of Endocrinology and Internal Medicine

Department of Molecular Medicine

Aarhus University Hospital

Aarhus University

Aarhus

Denmark

Disclosures

CHV has received honorariums within the last 3 years from Novo Nordisk, Merck, and Astra Zeneca for talks on Turner syndrome and endocrine side effects of protein kinase inhibitors.

Peer reviewers

Shanlee Davis, MD, PhD

Associate Professor

Pediatrics-Endocrinology

University of Colorado

Aurora

CO

Disclosures

SD serves as a site investigator for Ascendis Pharma on a long-acting growth hormone study. SD serves as a medical advisor for the non-profit organisation Living with XXY. SD has received research funding from the NIH, the Boettcher Foundation, the Pediatric Endocrine Society, AXYS, Living with XXY, and the Turner Syndrome Global Alliance.

Tet Yap, MB BChir, MD, MA, FRCS(Urol), FEBU

Consultant Andrological Surgeon

Guy's and St Thomas' Hospital NHS Foundation Trust

London

UK

Disclosures

TY declares that he has no competing interests.

Use of this content is subject to our disclaimer